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Treatment guidelines recommend lithium as a first-line option for relapse prevention and 
suicide prevention in bipolar-I-disorder. However, there is a disparity between research 
efficacy and clinical effectiveness, with only a third of patients having an excellent response 
to long-term treatment.1 Today, lithium use is in decline2 – the predominance of sub-optimal 
responses, the need for blood monitoring, the perception that lithium is more toxic than 
other medications and the often-lengthy trials necessary to determine response likely all 
contribute. For every factor, there is scope to improve our knowledge of lithium and room 
to move towards more effective, safe and ultimately personalised prescription. Such is the 
goal of the R-LiNK consortium (Response to Lithium Network; www.r-link.eu.com), but 
before considering this, we reflect on the history of lithium in this year of anniversaries.3 
In 1843, the aptly named Alexander Ure suggested lithium carbonate might treat urinary 
calculi but it was Garrod who first described its use 160 years ago (in gout and related brain 
maladies). 125 years ago, the Lange brothers reported on the use of lithium salts in 
periodical depression and Annie ‘Londonderry’ became the first female round-the-world 
cyclist, sponsored by the ‘lithia water’ company whose name she briefly adopted. Lithium 
salts were subsequently added to tonics (notably 7-UP, launched 90 years ago as ‘bib-
labelled lithiated lemon-lime soda’) and advocated as table salt substitutes for those with 
cardiac disease taking low sodium diets. The latter proved toxic and it was withdrawn from 
the US market in 1949.4 The same year, seventy years ago this month, also saw the 
publication of John Cade’s seminal paper describing its use in the treatment of mania.5  
Efficacy in mania was soon confirmed but perhaps the most important effect of lithium – the 
prevention of recurrence in bipolar disorder – was not a simple thing to establish.6 Even the 
notion of prophylaxis in psychiatry was contested and 50 years ago, debate raged (not least 
in The Lancet).7 Lithium was variously cast as panacea, placebo or poison. Technological 
advances in serum monitoring permitted the widespread clinical use of lithium but it was 
the development of novel trial methodology that provided the empirical evidence necessary 
to overcome the scepticism surrounding relapse prevention.3,6 Essentially, lithium did not 
benefit all, but proved remarkably effective for some. 
Response to lithium is an obvious stratification point. A predictor, discernable early in 
prophylaxis, could avoid the need for lengthy treatment trials and target lithium to those 
most likely to benefit. Regrettably, despite significant research effort, individual clinical 
markers and isolated biological markers inadequately inform practice due to low specificity, 
sensitivity and predictive power.1 An integrated science approach combining clinical and 
multimodal biomarkers may fare better. The ambition of R-LiNK is to determine which 
patients with bipolar disorder are most eligible for long-term lithium treatment in terms of 
response, safety and tolerability. We have established a large expert multidisciplinary 
European network with shared protocols and harmonised research procedures, supported 
by an international advisory committee. Here we share some innovations in our inaugural 
project, funded by the European Union Horizon 2020 program. 
In 16 centres, over 300 individuals will be enrolled in a prospective two-year cohort study of 
lithium in bipolar-I-disorder. In this representative sample, treatment decisions will remain 
rooted in clinical practice to enhance transferability of results. Brain imaging, blood 
molecular and metabolic biomarkers acquired before and 12 weeks after lithium initiation 
will capture intra-individual biological changes for testing with respect to long-term 
response. Monthly assessment during the follow-up period will allow precise evaluations of 
response and tolerance (such as ecological digital phenotypes, clinical symptoms, illness 
activity and adverse events) as well as treatment adherence (to avoid misclassification in 
response status). At conclusion, a consensus panel approach will classify individuals to a 
response category.  
We will test the predictive potential of clinical characteristics, digital phenotypes, omics and 
neuroimaging parameters as biomarkers and combined biosignatures, primarily against 
categorical response. More innovatively, we will assess response dimensionally, exploring 
the pace and pattern of change in a mirror image analysis, as well as its relationship to non-
response, non-adherence and poor tolerability. The study also embeds a health economic 
analysis.  
As an example of preparations, we have harmonised MRI sequences (structural, diffusion-
weighted and proton spectroscopy) across the different centres and scanners, with secure 
double-pseudomised data export systems embedding quality control measures. Novel to R-
LiNK, six centres have been equipped for 7Li-MRI, a new technique that directly measures 
brain lithium distribution,8 the heterogeneity of which may be related to therapeutic 
response and tolerance. Further, we have successfully combined 7Li-MRI with MRI measures 
of lithium’s tissue-level effects,9 including those with the potential to predict response.10  
Using machine-learning to combine clinical and multimodal biosignatures, we anticipate a 
‘prediction algorithm’ capable of guiding early treatment decisions (first three months) and 
avoiding the need for patients to submit to lengthy trials of lithium. We believe that the 
dissemination and application of harmonised methods will prove central to the development 
of personalised treatment in psychiatry, particularly for the validation studies envisaged.  
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